Global Aflibercept Market – Industry Trends and Forecast to 2030

Aflibercept Market Analysis and Size

Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Rise in the prevalence of wet maculat degeneration, metastatic colorectal cancer, visual impairment because of diabetic macular edema, and diabetic retinopathy will increase the market growth. Advancement of therapies for the treatment and increasing geriatric population are the expected factors that will increase the growth of aflibercept market. Growing government funds and support will also expand the aflibercept market.

Data Bridge Market Research analyses that the aflibercept market which was USD 8,343.15 million in 2022, and would rocket up to USD 13,911.94 million by 2030, and is expected to undergo a CAGR of 5.40% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user segment of the aflibercept market owing to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Aflibercept Market Scope and Segmentation

Market Definition

Aflibercept is a vascular endothelial growth factor-A (VEGF-A) antagonist which is used for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic retinopathy, and various types of muscular edema. It acts as a soluble decoy receptor which results in the binding of VEGF-A, VEGF-B, and placental growth factor (PIGF) and shows higher affinity. It is a medication which is traded under the brand names Eylea and Zaltrap.

Global Aflibercept Market Dynamics

Drivers

• Increasing  prevalence of ophthalmic conditions

Growing cases of wet maculat degeneration, metastatic colorectal cancer, visual impairment due to diabetic macular edema, and diabetic retinopathy will lead to an increased sale of aflibercept.

According to the World Health Organization, AMD affects approximately 196 million people worldwide, with over 10.4 million cases involving moderate to severe vision impairment. AMD is an eye disease that causes progressive central vision loss and affects the elderly primarily.

• Rising number of geriatric population

Expanding geriatric population worldwide is predicted to favour aflibercept demand as this population is more prone to cause eye diseases. The number of persons above 65 years is projected to double to 1.5 billion in 2050. Colorectal cancer (CRC) is the second leading cause of cancer death in the US. Globally, there were over 1.8 million new cases in 2018. The prevalence of visual impairment among the aging population ranges from 22% to 35%.

• Advancement of therapies for the treatment

Advancement of therapies for the treatment are the expected factors that will increase the growth of aflibercept market. An alarming increase in the rate of eyes being nonpersistent to monitoring visits and therapy results in more demand. Moreover, it is anticipated that the market for anti-VEGF therapeutics will exhibit lucrative growth, as several market participants are focusing on R&D to develop novel treatments. Participants are actively engaged in extensive research and development to develop novel drugs to treat various eye disorders and gain a larger market share. As the number of individuals with diseases continues to rise at an alarming rate, there is a growing demand for novel therapies and treatments.

Opportunity

• Increase in government funds

Furthermore, increase in government funds and support for target research activities, growing clinical trials and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030. Additionally, the expansion of money used by a country on its healthcare and its growth rate over the time is inclined by a wide variety of economic and social factors, including the financial agreements and structure of the organisation of the health system. This will further expand the market's growth rate in the future. 

Restraints/Challenges

• Presence of other alternative medications

On the other hand, presence of other alternative medications and trade barriers are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, are projected to challenge the market in the forecast period of 2023-2030.

This aflibercept market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aflibercept market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In September 2022, Regeneron Pharmaceuticals, Inc. has announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD) on 12- and 16-week dosing intervals. This demonstrated that dosing regimens of the drugs based on which Regeneron and Bayer would submit these data to regulatory authorities in countries around the world.

Global Aflibercept Market Scope

The aflibercept market is segmented on the basis of product, application, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Prefilled Syring Package
• Vial Package

Application

• Wet Macular Degeneration
• Metastatic Colorectal Cancer
• Diabetic Macular Oedema
• Diabetic Retinopathy
• Others

Route of Administration

• Intravenous
• Intravitreal Injection

End-User

• Hospitals
• Clinics
• Diagnostic centers
• Others)

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Aflibercept Market Regional Analysis/Insights

The aflibercept market is analysed and market size insights and trends are provided by country, product, application, route of administration, end user and distribution channel as referenced above.

The countries covered in the aflibercept market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.   

North America dominates the aflibercept market due to the existence of major key players, high prevalence rate, increasing social awareness, well-developed healthcare sector and increase in the government support for research & development in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to the growing focus of pharmaceutical companies on advancement of therapies for treatment, growing government support and rising healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The aflibercept market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for aflibercept market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the aflibercept market. The data is available for historic period 2010-2021.

Competitive Landscape and Aflibercept market Share Analysis

The aflibercept market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aflibercept market.

Some of the major players operating in the aflibercept market are:

• Bayer AG (Germany)
• Sanofi(France)
• Santen Pharmaceutical Co.,Ltd. (Japan)
• Regeneron Pharmaceuticals Inc.(U.S.)
•  F. Hoffmann-La Roche Ltd. (U.S.)
• Amgen Inc. (U.S.)
• Pfizer, Inc. (U.S.)
• Xbrane Biopharma AB (Sweden)
• Allergan (Ireland)
• Viatris Inc. (U.S.)

SKU-63716